INMB - Inmune Bio Inc Stock Price, Fair Value and News

$1.77+0.20 (+12.74%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

INMB Price Action

Last 7 days

7.3%

Last 30 days

-1.7%

Last 90 days

-7.8%

Trailing 12 Months

-65.8%

INMB RSI Chart

INMB Valuation

Market Cap

47.1M

Price/Earnings (Trailing)

-0.94

Price/Sales (Trailing)

941.12

Price/Free Cashflow

-1.69

INMB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

INMB Fundamentals

INMB Revenue

Revenue (TTM)

50.0K

Rev. Growth (Yr)

257.14%

Rev. Growth (Qtr)

-100%

INMB Earnings

Earnings (TTM)

-49.9M

Earnings Growth (Yr)

46.48%

Earnings Growth (Qtr)

73.54%

INMB Profitability

Return on Equity

-196.58%

Return on Assets

-149.55%

Free Cashflow Yield

-59.3%

INMB Investor Care

Shares Dilution (1Y)

19.90%

Diluted EPS (TTM)

-2.12

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	50.0K	50.0K	50.0K	0
2024	131.0K	85.0K	42.0K	14.0K
2023	249.0K	279.0K	224.0K	155.0K
2022	340.0K	356.0K	440.0K	374.0K
2021	53.5K	96.0K	138.5K	181.0K
2020	0	0	0	11.0K
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Inmune Bio Inc

INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

CEO	Dr. Raymond Joseph Tesi M.D.
WEBSITE	inmunebio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	10

Inmune Bio Inc Frequently Asked Questions

What is the ticker symbol for Inmune Bio Inc? What does INMB stand for in stocks?

INMB is the stock ticker symbol of Inmune Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inmune Bio Inc (INMB)?

As of Wed Dec 03 2025, market cap of Inmune Bio Inc is 47.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INMB stock?

You can check INMB's fair value in chart for subscribers.

Is Inmune Bio Inc a good stock to buy?

The fair value guage provides a quick view whether INMB is over valued or under valued. Whether Inmune Bio Inc is cheap or expensive depends on the assumptions which impact Inmune Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INMB.

What is Inmune Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, INMB's PE ratio (Price to Earnings) is -0.94 and Price to Sales (PS) ratio is 941.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INMB PE ratio will change depending on the future growth rate expectations of investors.